Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD.
Obstetrics and Gynaecology, DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
Int J Cancer. 2020 May 15;146(10):2836-2844. doi: 10.1002/ijc.32919. Epub 2020 Feb 22.
Identification of high-risk human papillomavirus genotypes causing cervical precancer is crucial for informing HPV vaccine development and efficacy studies, and for determining which types to include in next-generation genotyping assays. Co-occurrence of hrHPV infections is common and complicates carcinogenicity assessment; accurate attribution requires tissue-based genotyping of precancers. We included all women with cervical intraepithelial neoplasia Grade 2 or worse (CIN2+) from the Biopsy Study, an observational study of 690 women enrolled between 2009 and 2012 at the University of Oklahoma. Tissue-based genotyping, including whole tissue sections (WTS) and laser-capture microdissection (LCM), was performed on all precancers with multiple hrHPV infections detected in cytology, totaling over 1,800 HPV genotyping assays. Genotype attribution was compared to hierarchical and proportional hrHPV-type attribution models. Of 276 women with CIN2+, 122 (44.2%) had multiple hrHPV genotypes in cytology. Of 114 women with genotyping data, 94 had one or more hrHPV detected in tissue. Seventy-one women (75.5%) had a single causal hrHPV genotype, while 23 women had multiple hrHPV genotypes causing CIN2+. Ten women had multiple causal infections in a single biopsy, contrary to the previous notion that each lesion is caused by a single type only. While HPV16 was the predominant causal hrHPV genotype using all approaches, the hierarchical model overattributed HPV16, whereas other causal hrHPV genotypes, particularly HPV18 and HPV35, were underattributed. Understanding true causal genotypes is important for the evaluation of vaccine efficacy, to estimate the extent of unmasking, and for type-specific risk assessment in screening and management.
识别导致宫颈癌前病变的高危型人乳头瘤病毒(hrHPV)基因型对于告知 HPV 疫苗开发和疗效研究、确定包含在下一代基因分型检测中的类型至关重要。hrHPV 感染的共同发生很常见,并且使致癌性评估变得复杂;准确归因需要对癌前病变进行基于组织的基因分型。我们纳入了来自活检研究的所有宫颈上皮内瘤变 2 级或更高级别(CIN2+)的女性,该研究是一项观察性研究,纳入了 2009 年至 2012 年期间在俄克拉荷马大学入组的 690 名女性。对所有细胞学检测到多个 hrHPV 感染的癌前病变进行了基于组织的基因分型,包括全组织切片(WTS)和激光捕获微切割(LCM),总共进行了超过 1800 次 HPV 基因分型检测。将基因分型归因与分层和比例型 HPV 型归因模型进行了比较。在 276 名 CIN2+女性中,122 名(44.2%)在细胞学检查中发现了多种 hrHPV 基因型。在 114 名具有基因分型数据的女性中,94 名女性的组织中检测到一种或多种 hrHPV。71 名女性(75.5%)有一种单一的因果性 HPV 基因型,而 23 名女性有多种 HPV 基因型导致 CIN2+。10 名女性在单个活检中有多种因果感染,这与之前认为每个病变仅由单一类型引起的观点相反。虽然使用所有方法 HPV16 都是主要的因果性 HPV 基因型,但分层模型过度归因于 HPV16,而其他因果性 HPV 基因型,特别是 HPV18 和 HPV35,则归因不足。了解真正的因果基因型对于评估疫苗疗效、估计去掩饰程度以及在筛查和管理中进行特定类型的风险评估都很重要。